deltatrials
Unknown PHASE2 NCT00303745

Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Randomized Study of Second-Line Therapy Comprising Irinotecan With or Without Capecitabine in Patients Aged At Least 75 Years With Colorectal Cancer

Sponsor: Federation Francophone de Cancerologie Digestive

Conditions Colorectal Cancer
Interventions capecitabine irinotecan hydrochloride
Updated 6 times since 2017 Last updated: Jul 23, 2008 Started: Jun 30, 2006

A PHASE2 clinical study on Colorectal Cancer, this trial is ongoing. The trial is conducted by Federation Francophone de Cancerologie Digestive and has accumulated 6 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

    First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Federation Francophone de Cancerologie Digestive
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abbeville, France, Boucher, France, Boulogne, France, Chalon-sur-Saône, France, Clamart, France, Dijon, France, Guilherand-Granges, France, Le Havre, France, Le Mans, France, Libourne, France and 10 more location s